Nerve growth factor regulates the expression of vascular endothelial growth factor in human HaCaT keratinocytes via PI3K/mTOR pathway

Genetics and Molecular Research

Volumn 13, Issue 4, 2014, Pages 9324-9335

  Zhang, J ^a   Ma, W Y ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Hypoxia inducible factor 1 ; Keratinocytes; Nerve growth factor; Psoriasis; Vascular endothelial growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NERVE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; VASCULOTROPIN; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; FLAVONOID; MITOGEN ACTIVATED PROTEIN KINASE; MTOR PROTEIN, HUMAN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ARTICLE; CONTROLLED STUDY; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; KERATINOCYTE; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; CELL LINE; DRUG EFFECTS; GENETICS; METABOLISM;

CELL LINE; FLAVONOIDS; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KERATINOCYTES; MITOGEN-ACTIVATED PROTEIN KINASES; NERVE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3-KINASES; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84909952958     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.January.24.14     Document Type: Article

References (37)

1. Basavaraj KH, Navya MA and Rashmi R (2011). Stress and quality of life in psoriasis: an update. Int. J. Dermatol. 50: 783-792.
2. Botchkarev VA, Yaar M, Peters EM, Raychaudhuri SP, et al. (2006). Neurotrophins in skin biology and pathology. J. Invest. Dermatol. 126: 1719-1727.
3. Buchau AS and Gallo RL (2007). Innate immunity and antimicrobial defense systems in psoriasis. Clin. Dermatol. 25: 616-624.
4. Calza L, Giardino L, Giuliani A, Aloe L, et al. (2001). Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors. Proc. Natl. Acad. Sci. U. S. A. 98: 4160-4165.
5. Cantarella G, Lempereur L, Presta M, Ribatti D, et al. (2002). Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J. 16: 1307-1309.
6. Castellani ML, Galzio RJ, Felaco P, Tripodi D, et al. (2010). VEGF, substance P and stress, new aspects: a revisited study. J. Biol. Regul. Homeost. Agents 24: 229-237.
7. Geilen CC, Bektas M, Wieder T, Kodelja V, et al. (1997). 1α, 25-dihydroxyvitamin D3 induces sphingomyelin hydrolysis in HaCaT cells via tumor necrosis factor α. J. Biol. Chem. 272: 8997-9001.
8. Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF, et al. (1991). High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature 350: 678-683.
9. Johnson D, Lanahan A, Buck CR, Sehgal A, et al. (1986). Expression and structure of the human NGF receptor. Cell 47: 545-554.
10. Kaplan DR, Hempstead BL, Martin-Zanca D, Chao MV, et al. (1991). The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 252: 554-558.
11. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, et al. (2003). Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc. Natl. Acad. Sci. U. S. A. 100: 9090-9095.
12. Kim Y, Kim BH, Lee H, Jeon B, et al. (2011). Regulation of skin inflammation and angiogenesis by EC-SOD via HIF-1α and NF-κβ pathways. Free Radic. Biol. Med. 51: 1985-1995.
13. Klein R, Jing SQ, Nanduri V, O’Rourke E, et al. (1991). The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 65: 189-197.
14. Kwon YW, Kwon KS, Moon HE, Park JA, et al. (2004). Insulin-like growth factor-II regulates the expression of vascular endothelial growth factor by the human keratinocyte cell line HaCaT. J. Invest. Dermatol. 123: 152-158.
15. Lappano R and Maggiolini M (2011). G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 10: 47-60.
16. Man XY, Yang XH, Cai SQ, Bu ZY, et al. (2008). Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J. Cell Mol. Med. 12: 649-660.
17. Marconi A, Vaschieri C, Zanoli S, Giannetti A, et al. (1999). Nerve growth factor protects human keratinocytes from ultraviolet-B-induced apoptosis. J. Invest. Dermatol. 113: 920-927.
18. Matsuo T, Stauffer JK, Walker RL, Meltzer P, et al. (2000). Structure and promoter analysis of the human unc-33-like phosphoprotein gene. E-box required for maximal expression in neuroblastoma and myoblasts. J. Biol. Chem. 275: 16560-16568.
19. Menter A and Griffiths CE (2007). Current and future management of psoriasis. Lancet 370: 272-284.
20. Montano JA, Pérez-Pinera P, García-Suárez O, Cobo J, et al. (2010). Development and neuronal dependence of cutaneous sensory nerve formations: Lessons from neurotrophins. Microsc. Res. Tech. 73: 513-529.
21. Muller K and Prinz H (1997). Antipsoriatic anthrones with modulated redox properties. 4. Synthesis and biological activity of novel 9, 10-dihydro-1, 8-dihydroxy-9-oxo-2-anthracenecarboxylic and -hydroxamic acids. J. Med. Chem. 40: 2780-2787.
22. Nakamura M, Toyoda M and Morohashi M (2003). Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br. J. Dermatol. 149: 718-730.
23. Nakamura K, Martin KC, Jackson JK, Beppu K, et al. (2006). Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1α in neuroblastoma cells. Cancer Res. 66: 4249-4255.
24. Nakamura K, Tan F, Li Z and Thiele CJ (2011). NGF activation of TrkA induces vascular endothelial growth factor expression via induction of hypoxia-inducible factor-1α. Mol. Cell Neurosci. 46: 498-506.
25. Nestle FO, Kaplan DH and Barker J (2009). Psoriasis. N. Engl. J. Med. 361: 496-509.
26. Nithya M, Suguna L and Rose C (2003). The effect of nerve growth factor on the early responses during the process of wound healing. Biochim. Biophys. Acta 1620: 25-31.
27. Raychaudhuri SK and Raychaudhuri SP (2009). NGF and its receptor system: a new dimension in the pathogenesis of psoriasis and psoriatic arthritis. Ann. N. Y. Acad. Sci. 1173: 470-477.
28. Raychaudhuri SP, Jiang WY and Farber EM (1998). Psoriatic keratinocytes express high levels of nerve growth factor. Acta Derm. Venereol. 78: 84-86.
29. Raychaudhuri SP, Jiang WY, Smoller BR and Farber EM (2000). Nerve growth factor and its receptor system in psoriasis. Br. J. Dermatol. 143: 198-200.
30. Ren X, Li J, Zhou X, Luo X, et al. (2009). Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model. Dermatology 219: 232-238.
31. Rosenberger C, Solovan C, Rosenberger AD, Jinping L, et al. (2007). Upregulation of hypoxia-inducible factors in normal and psoriatic skin. J. Invest. Dermatol. 127: 2445-2452.
32. Shelling ML, Federman DG, Prodanovich S and Kirsner RS (2008). Psoriasis and vascular disease: an unsolved mystery. Am. J. Med. 121: 360-365.
33. Sugiura H, Omoto M, Hirota Y, Danno K, et al. (1997). Density and fine structure of peripheral nerves in various skin lesions of atopic dermatitis. Arch. Dermatol. Res. 289: 125-131.
34. Takaoka K, Shirai Y and Saito N (2009). Inflammatory cytokine tumor necrosis factor-α enhances nerve growth factor production in human keratinocytes, HaCaT cells. J. Pharmacol. Sci. 111: 381-391.
35. Taniguchi M, Matsuzaki S and Tohyama M (2007). P75 plays a key role in the induction of the sprouting of sensory nerve fibers in inflamed skin. J. Invest. Dermatol. 127: 2062-2065.
36. Urpe M, Buggiani G and Lotti T (2005). Stress and psychoneuroimmunologic factors in dermatology. Dermatol. Clin. 23: 609-617.
37. Yu XJ, Li CY, Wang KY and Dai HY (2006). Calcitonin gene-related peptide regulates the expression of vascular endothelial growth factor in human HaCaT keratinocytes by activation of ERK1/2 MAPK. Regul. Pept. 137: 134-139.